amgen
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background Regulatory guidelines governing the development of biosimilars require that proposed biosimilars undergo comprehensive…
Background: Ibrutinib is a first-in-class selective, irreversible inhibitor of Bruton9s tyrosine kinase (BTK) approved for the…
A strategic imperative for Amgen is to increase the
number of patients that have access to the company's lifesaving
medicines. As…
Antibody-based immunotherapy represents a promising strategy to target and eliminate chemoresistant leukemic cells in acute…
Background Rheumatoid arthritis (RA), psoriasis (PsO) and psoriatic arthritis (PsA) are associated with increased risk of CV…
PURPOSE
The Medicare program authority, structure, and current and proposed rules for and rates of pharmaceutical reimbursement…
In a move aimed at reinforcing its presence in the oncology field, Amgen signed a deal to purchase Abgenix.
With seemingly novel science, unsatisfactory existing treatment options and a sizeable potential patient population, it’s hard to…
Amgen has launched darbepoetin alfa, synthetic recombinant novel erythropoiesis stimulating protein (NESP), for the treatment of…
An arbitration panel in Chicago has awarded Amgen (Thousand Oaks, CA) exclusive rights to its next-generation anemia drug, novel…